<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03367780</url>
  </required_header>
  <id_info>
    <org_study_id>N17DSI</org_study_id>
    <nct_id>NCT03367780</nct_id>
  </id_info>
  <brief_title>Dose‐Effect Relation of Salivary Gland Irradiation</brief_title>
  <official_title>Determining the Dose‐Effect Relation of Salivary Gland Irradiation and Cell Loss With PSMA PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optimization of radiotherapy to reduce xerostomia is difficult, because many gland locations
      cannot be seen with current imaging modalities and biological dose‐effect are currently
      insufficiently understood. PSMA PET is a new diagnostic instrument which can visualize the
      presence of vital acinar cells in salivary gland locations throughout the head and neck, with
      a sensitive and quantitative signal. A reduction of PSMA accumulation in salivary glands is
      thought to correlate with loss of vital acinar cells. The PET images can be correlated with
      radiotherapy dose distributions in gland‐based or voxel‐based evaluations. This makes PSMA
      PET a suitable instrument to derive the radiobiological dose‐effect relations that are
      required to develop better and gland‐specific dose constraints for radiotherapy. The results
      of this study can contribute to lower toxicity and better quality of life in patients treated
      with high‐dose radiotherapy in the head and neck.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective of this prospective observational study is to determine the gland‐based
      dose‐effect relation between conventionally fractionated radiotherapy (RT) and long‐term loss
      of acinar cells, per salivary gland type. The study population consists of a maximum of 20
      patients with HNSCC referred for high‐dose (CC)RT. There is no therapeutic intervention.
      Diagnostic intervention is PSMA PET/CT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the mean received radiation dose to salivary glands (Dmean), and the total uptake of PSMA in salivary glands (SUVtotal) and its relative reduction after radiotherapy (ΔSUVtotal‐6).</measure>
    <time_frame>6 months</time_frame>
    <description>Dmean and ΔSUVtotal‐6 are correlated to determine the dose‐effect relation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ΔSUV</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the clinical evaluation of a dry mouth</measure>
    <time_frame>before treatment, once during 7 weeks of treatment and follow up 6 months after</time_frame>
    <description>according to the C30+HN35 QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the clinical evaluation of a dry mouth</measure>
    <time_frame>before treatment, once a week during 7 weeks of treatment and follow up 6 months after</time_frame>
    <description>Groningen questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>voxel-based ΔSUV</measure>
    <time_frame>7 weeks of treatment, follow-up 1 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voxel-based received radiation dose</measure>
    <time_frame>7 weeks of treatment, 1 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HNSCC</condition>
  <arm_group>
    <arm_group_label>RT with curative intent for HNSCC</arm_group_label>
    <description>several schemes for radical (chemo)radiotherapy, administered in 30‐35 fractions over 6‐7 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PSMA PET/CT-scan</intervention_name>
    <description>PSMA PET is a new diagnostic instrument which can visualize the presence of vital acinar cells in salivary gland locations throughout the head and neck, with a sensitive and quantitative signal.</description>
    <arm_group_label>RT with curative intent for HNSCC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with proven mucosal squamous cell carcinoma in the head‐neck area who are referred
        for high dose EBRT based on current clinical criteria. AVL currently treats multiple new
        patients per week, and with an inclusion rate of 50% this observational study can complete
        inclusion well within one year. The study will close after 6 months of follow‐up of the
        last included patient, for an expected total study duration of 1.5 years.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HNSCC of the head‐neck area, cTx‐4 N0‐3 M0

          -  Accepted for EBRT in a conventionally fractionated schedule of 6‐7 weeks.

        Exclusion Criteria:

          -  Age &lt;18y

          -  Pregnancy or lactation

          -  Participation in conflicting studies, e.g. with non‐standard treatment and/or imaging

          -  Inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wouter V Vogel, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wouter V Vogel, MD, PhD</last_name>
    <phone>+31205122267</phone>
    <email>w.vogel@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilia Owers, MD</last_name>
    <phone>+31 20 512 7917</phone>
    <email>e.owers@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute- Antoni van Leeuwenhoek (NKI-AVL)</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W.V. Vogel, MD,PhD</last_name>
      <phone>+31 20 512 2267</phone>
      <email>w.vogel@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>E. Owers, MD</last_name>
      <phone>+31 20 512 7917</phone>
      <email>e.owers@nki.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roel J.H.M. Steenbakkers, MD, PhD</last_name>
      <phone>+31 50 3619382</phone>
      <email>r.steenbakkers@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Anneke de Haan, MD</last_name>
      <phone>+31 50 3610473</phone>
      <email>a.de.haan01@umcg.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bart de Keizer, MD,PhD</last_name>
      <phone>+316 24873273</phone>
      <email>b.dekeizer@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Tjitske Kent-Bosma</last_name>
      <email>tbosma@umcutrecht.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head-neck tumours</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Salivary gland toxicity</keyword>
  <keyword>PSMA PET/CT</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

